Danaher (NYSE:DHR) Stock Acquired Rep. Lisa C. McClain

Key Points

• Representative Lisa C. McClain recently purchased shares of Danaher Corporation (NYSE:DHR), investing between $1,001 and $15,000 on July 22nd, 2025.
• Danaher reported a quarterly EPS of $1.80, exceeding the estimated $1.64, with revenues of $5.94 billion for the quarter.
• Hedge funds have shown significant interest in Danaher, with institutional investors holding 79.05% of the company's stock, highlighting strong institutional support.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Danaher Corporation NYSE: DHR. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Danaher stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Danaher Stock Performance

Shares of DHR stock traded down $0.6530 during trading hours on Wednesday, reaching $211.5470. 1,282,983 shares of the company's stock were exchanged, compared to its average volume of 4,222,099. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The company's 50 day moving average is $200.33 and its two-hundred day moving average is $199.54. The company has a market cap of $151.48 billion, a P/E ratio of 45.02, a price-to-earnings-growth ratio of 2.92 and a beta of 0.73. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the business earned $1.72 earnings per share. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on DHR shares. Royal Bank Of Canada reiterated an "outperform" rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Wells Fargo & Company reduced their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Robert W. Baird increased their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Finally, JPMorgan Chase & Co. reduced their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 22nd. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus target price of $247.61.

Institutional Trading of Danaher

A number of hedge funds have recently added to or reduced their stakes in DHR. B. Riley Wealth Advisors Inc. acquired a new position in Danaher during the second quarter worth approximately $574,000. Marex Group plc purchased a new stake in shares of Danaher during the 2nd quarter valued at $3,124,000. Anchor Investment Management LLC increased its holdings in shares of Danaher by 3.8% during the 2nd quarter. Anchor Investment Management LLC now owns 8,931 shares of the conglomerate's stock worth $1,764,000 after buying an additional 324 shares during the last quarter. Asset Dedication LLC raised its position in shares of Danaher by 6.8% in the 2nd quarter. Asset Dedication LLC now owns 3,634 shares of the conglomerate's stock worth $718,000 after buying an additional 232 shares during the period. Finally, Liontrust Investment Partners LLP boosted its holdings in Danaher by 32.7% in the second quarter. Liontrust Investment Partners LLP now owns 121,031 shares of the conglomerate's stock valued at $23,908,000 after acquiring an additional 29,791 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.